BSE filing, NSE: BHAGERIA. Summary written from the filing by ALFA Finder's alert engine.
Bhageria Industries Ltd: key numbers
- Share price
- ₹364.80
- Market cap
- ₹1,592 Cr
- Revenue (annual)
- ₹874.0 Cr
- Net profit (annual)
- ₹46.08 Cr
- P/E (TTM)
- 14.1×Sector 26.4×
- Promoter holding
- 71.85%+0.08% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bhageria Industries Ltd
All →Bhageria Industries Q2 FY27 Results: Net Profit ₹55.7 Cr, Up 384.3% YoY
Bhageria Industries Ltd reported revenue from operations of ₹455.7 Cr (+122.9% YoY) and net profit of ₹55.7 Cr (+384.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹55.7 Cr · +384.3% YoY
Bhageria Industries Legal & Regulatory
SAT adjourned Bhageria Industries' appeal against SEBI's March 2023 adjudication order, now set for January 5, 2027. The SEBI order remains stayed pending final disposal.
Bhageria Industries Board Meeting Date
Bhageria Industries has scheduled a Board meeting on 28 Oct 2026 to approve unaudited Q2 and H1 FY27 results. The trading window remains closed until 48 hours post-declaration.
Bhageria Industries Other Announcement
Bhageria Industries Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Bhageria Industries Credit Rating
CARE Ratings reaffirmed the credit rating for Bhageria Industries' bank facilities of ₹141.00 Crore and removed them from the 'Rating Watch with Negative Implications'.
Bhageria Industries Credit Rating
CARE Ratings reaffirmed Bhageria Industries Limited's ratings at 'CARE A; Stable / CARE A1' for bank facilities worth ₹91.00 Crore. The outlook was assigned as stable after removal from 'Rating Watch with Negative Implications'.
- Value
- ₹91.00 Cr
Other regulatory approval announcements
All →Senores Pharmaceuticals Regulatory Approval
Senores Pharmaceuticals disclosed that its subsidiary Ratnatris Pharmaceuticals' Mehsana facility received PIC/S GMP certification from Ukraine's SMDC. The certificate, issued 16 November 2026, opens a wider pathway to regulatory approvals.
Xtglobal Infotech Regulatory Approval
XTGlobal received RBI approval for a ₹0.10 Crore (EUR 10,000) equity investment in its Irish subsidiary. The initial capital supports its European expansion plans.
- Value
- ₹0.10 Cr
Regal Entertainment & Consultants Regulatory Approval
Regal Entertainment received RBI approval for Satbir Singh's appointment as Executive Director. Shareholder approval is still pending, with the term running to April 4, 2028.
Biocon Regulatory Approval
Biocon received U.S. FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, its fifth oncology biosimilar approved in the US. A global settlement with Genentech sets the earliest US launch in Q3 2028.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Binimetinib tablets, securing 180 days of generic drug exclusivity for the product.
United Breweries Regulatory Approval
United Breweries received BIADA's final order restoring its 42-acre Patna land allotment under the Amnesty Policy 2025, subject to conditions. Commercial production milestones must be met within 24 months.